For the 7th year running, Roche ranked most sustainable healthcare company in the Dow Jones Sustainability Indices
- Details
- Category: Roche
For the seventh consecutive year, Roche (SIX: RO, ROG; OTCQX: RHHBY) has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry. "We are very proud of this recognition," said Roche CEO Severin Schwan.
Abbott named industry leader for responsible and sustainable business for three consecutive years on the Dow Jones Sustainability Index (DJSI)
- Details
- Category: Abbott
For the third consecutive year, Abbott (NYSE: ABT) has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate responsibility and sustainability. As the Industry Group Leader in Health Care Equipment & Services, Abbott is the only U.S.-based company of the 24 companies recognized for leading their respective industry groups.
AstraZeneca purchases US biologics manufacturing facility to support growing pipeline
- Details
- Category: AstraZeneca
AstraZeneca today added to its biologics manufacturing capability in the US with the purchase of a high-tech biologics bulk manufacturing facility from Amgen Inc. Over time, the LakeCentre facility, located in Boulder, Colorado will increase manufacturing and production capacity to support the company’s extensive portfolio of biologics medicines.
Bristol-Myers Squibb Employees cycle nearly 2,900 miles to raise money for cancer research
- Details
- Category: Bristol-Myers Squibb
Today, members of the Bristol-Myers Squibb (NYSE:BMY) oncology team set off on the first leg of the Coast 2 Coast 4 Cancer Ride, a 19-day bike relay that will involve over 80 employees riding a combined total of nearly 2,900 miles, from today's start on the Oregon Coast to the Jersey Shore, to show their support for the cancer community while raising funds for cancer research.
AstraZeneca to invest £11.5 million in new clinical oncology bioinformatics collaboration with The University of Manchester
- Details
- Category: AstraZeneca
AstraZeneca and The University of Manchester today announced a collaboration harnessing clinical bioinformatics to deliver personalised healthcare for cancer patients. The five-year agreement will see the organisations apply clinical trial bioinformatics to better identify the right cancer treatment for the right patient at the right time.
Novo Nordisk and MIT to collaborate on researching the next generation of drug delivery devices
- Details
- Category: Novo Nordisk
Novo Nordisk today announced that a research collaboration has been initiated with the Langer Laboratory at the Massachusetts Institute of Technology for what is hoped to be the next generation of drug delivery devices for the administration of peptides.
Novartis receives EU approval for Farydak®, the first in its class of anticancer agents approved for patients with multiple myeloma
- Details
- Category: Novartis
Novartis announced today that the European Commission has approved Farydak® (panobinostat, previously known as LBH589) capsules, in combination with bortezomib* and dexamethasone, for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent (IMiD).
More Pharma News ...
- US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack
- Sanofi to collaborate with Google life sciences to improve diabetes health outcomes
- Novartis announces global partnership with Amgen to develop and commercialize pioneering neuroscience treatments
- AstraZeneca and Valeant Pharmaceuticals to partner on brodalumab
- Novo Nordisk plans 2 billion US dollar investment in new production facilities in Clayton, North Carolina and Måløv, Denmark
- AstraZeneca and Peregrine Pharmaceuticals to collaborate on immuno-oncology combination clinical trial
- Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications